Arrowhead Pharmaceuticals, Inc.
ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial toā¦ read more
Healthcare
Biotechnology
32 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$82.76
Price+0.16%
$0.13
1Y
Price
Market Cap
$11.657b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-205.1%
EBITDA Margin-258.2%
Net Profit Margin-240.9%
Free Cash Flow Margin-205.1%
EBITDA Margin-258.2%
Net Profit Margin-240.9%
Free Cash Flow MarginRevenue
$669.495m
-19.3%
1y CAGR+7713.5%
3y CAGR+5784.8%
5y CAGREarnings
-$319.951m
-19516.9%
1y CAGR-6536.4%
3y CAGR-4906.4%
5y CAGREPS
-$2.24
-22300.0%
1y CAGR-7453.5%
3y CAGR-5593.9%
5y CAGRBook Value
$466.041m
$2.112b
Assets$1.646b
Liabilities$864.073m
DebtDebt to Assets
40.9%
-6.2x
Debt to EBITDAFree Cash Flow
-$75.111m
-147.9%
1y CAGR-34.9%
3y CAGR-44.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company